Comparative Safety Profiles of Bevacizumab, Ranibizumab and Pegaptanib in the Treatment of Age-Related Macular Degeneration: the Analysis of the WHO Database of Adverse Drug Reactions

被引：0
|
作者：
Biagi, Chiara [1 ]
Conti, Valentino [2 ]
Bonisolli, Marta [1 ]
Melis, Mauro [1 ]
Buccellato, Elena [1 ]
Covezzoli, Anna [3 ]
Amato, Roberta [3 ]
Pazzi, Linda [3 ]
Venegoni, Mauro [2 ]
Vaccheri, Alberto [1 ]
Motola, Domenico [1 ]
机构：
[1] Univ Bologna, Dept Med & Surg Sci, Pharmacol Unit, Bologna, Italy
[2] Reg Ctr Pharmacovigilance, Milan, Lombardy Region, Italy
[3] CINECA, Interuniv Consortium, Hlth Care Syst Dept, Bologna, Italy
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2014年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
522
引用
收藏
页码：276 / 276
页数：1
相关论文
共 50 条
  • [1] Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions
    Biagi, C.
    Conti, V.
    Montanaro, N.
    Melis, M.
    Buccellato, E.
    Donati, M.
    Covezzoli, A.
    Amato, R.
    Pazzi, L.
    Venegoni, M.
    Vaccheri, A.
    Motola, D.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (12) : 1505 - 1512
  • [2] Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions
    C. Biagi
    V. Conti
    N. Montanaro
    M. Melis
    E. Buccellato
    M. Donati
    A. Covezzoli
    R. Amato
    L. Pazzi
    M. Venegoni
    A. Vaccheri
    D. Motola
    European Journal of Clinical Pharmacology, 2014, 70 : 1505 - 1512
  • [3] Treatment of neovascular age-related macular degeneration with pegaptanib and boosting with bevacizumab or ranibizumab as needed
    Farah, Samer E.
    OPHTHALMIC SURGERY LASERS & IMAGING, 2008, 39 (04) : 294 - 298
  • [4] Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration
    Martin, Daniel F.
    Maguire, Maureen G.
    Fine, Stuart L.
    Ying, Gui-shuang
    Jaffe, Glenn J.
    Grunwald, Juan E.
    Toth, Cynthia
    Redford, Maryann
    Ferris, Frederick L., III
    OPHTHALMOLOGY, 2012, 119 (07) : 1388 - 1398
  • [5] Comparative Review of Ranibizumab versus Bevacizumab in the Treatment of Neovascular Age-related Macular Degeneration
    Heroman, J. Wesley
    Kaplan, Henry J.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2010, 2 : 491 - 497
  • [6] Pegaptanib for the treatment of age-related macular degeneration
    Zhou, Bo
    Wang, Bin
    EXPERIMENTAL EYE RESEARCH, 2006, 83 (03) : 615 - 619
  • [7] EFFICACY AND SAFETY OF RANIBIZUMAB AND BEVACIZUMAB IN TREATMENT FOR AGE RELATED MACULAR DEGENERATION
    Saturnino, L. T. M.
    Silveira, M. R.
    Guerra Junior, A. A.
    Acurcio, F. D. A.
    VALUE IN HEALTH, 2013, 16 (07) : A667 - A668
  • [8] Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration
    Hughes, Mark S.
    Sang, Delia N.
    OPHTHALMIC SURGERY LASERS & IMAGING, 2006, 37 (06) : 446 - 454
  • [9] Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review
    Takeda, A. L.
    Colquitt, J.
    Clegg, A. J.
    Jones, J.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2007, 91 (09) : 1177 - 1182
  • [10] Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration
    Abouammoh, Marwan
    Sharma, Sanjay
    CURRENT OPINION IN OPHTHALMOLOGY, 2011, 22 (03) : 152 - 158
12345